日日噜夜夜草|一级黄色录像高清版|调教白富美加勒比久久|亚洲欧洲精品婷婷|日韩综合无码色色|日韩精品一区妖精视频|亚洲无码中文字幕hd|99亚洲思思丝袜|手机看片国产精品大胆亚洲|成人无码视频一区二区在线播放

更新于 3月21日

輝瑞制藥-高級醫(yī)學(xué)顧問 Sr.MA-抗感染

2.1-2.7萬
  • 上海靜安區(qū)
  • 1-3年
  • 博士
  • 全職
  • 招1人

雇員點(diǎn)評標(biāo)簽

  • 同事很nice
  • 團(tuán)隊(duì)執(zhí)行強(qiáng)
  • 工作環(huán)境好
  • 人際關(guān)系好
  • 氛圍活躍
  • 實(shí)力大公司

職位描述

藥企
To advise and manage medical related activities in all operations of company with medical expertise and company policies, with the objective of ensuring the scientific validity and the ethics of operations. 1. Enhance local data generation and Product life-cycle management from medical perspective to maximize product’s value and long term development
  • Evaluate new products, new indications, new research programs, new business potentials of defined therapeutic areas from medical perspective to support new product introduction and line extension
  • Align with cross function team including marketing, CCO team, global team etc, develop post marketing research strategy based on Registration/Market needs
  • Provide phase IV study direction and develop key elements
  • Design and manage local Non-interventional Study (NIS) study as a clinician.
  • Develop medical strategy and implement it to support product development
  • Develop publication plan and implement it
  • Evaluate and review Investigator Initiate research proposal to ensure its scientific standard and strategy fit
2. As a key partner to provide medical input on business decision making
  • Co-develop product strategy, positioning, key message with Marketing team
  • Provide medical support (topic design, KOL communication etc.) on key marketing activities
  • Provide broad and deep medical insight/summary document of the defined therapeutic area to business partners to deal with key product issues such as bidding, RDL, new initiatives etc.
  • Review and approve Local Standard Response Letter to HCPs
3. Develop sale force’s medical capability through training program design, Lecture Delivery and periodic medical knowledge update in different settings through various channel
  • At Phase I sales training
  • At National sales conference
  • Field visit
  • Special sales force program
  • Give lectures or updates to other stakeholders to increase their disease and product knowledge
4. Support Drug Registration Activities
  • Timely review and approval of local product labeling (LPD)
  • Develop medical justification document to support LPD related queries from government
  • Provide medical input in feasibility evaluation of studies for global trials
  • Provide official input on study site selection from therapeutic prospective
  • Provide input to registration protocol synopsis and study report as necessary
5. Academic communication to enhance the delivery of new concept and Pfizer products key message to key influencers and stakeholders, and Establish Cooperation and partnership with medical association to promote medical advancement.
  • Set up national level KOL database, and keep medical communication with through various approaches
  • Design educational programs for top KOLs and implement them
  • Support on China treatment guideline development, scientific interpretation and promotion
  • Publish or facilitate publication of medical paper in professional journals
  • Cooperation with local medical societies to conduct medical programs/conference to facilitate new concept and state of art medical progress’ introduction to China
6. In order to maintain company’s image and protect patient’s welfare, MA act as a core member to work with cross function team on crisis management.
  • Perform medical evaluation, explanation on the event;
  • Develop medical justification or responding document.
  • Provide medical expert opinion on company responding strategy
  • Review and approve all external communication documents to make sure all delivered message are medically precise and consistent
  • Communicate with external customers directly for medical issues as necessary
7. Provide medical expert opinion in safety events management to avoid negative impact.
  • Provide professional medical consultation to Safety Officer to solve Pfizer products’ safety query
  • If take clinician role: provide the clinical safety oversight including performing and documenting regular review of individual subject safety data and performing review of cumulative safety data with the safety risk lead (as delegated by the clinical lead).
  • If take clinical lead role: consistent with Safety Review Plan (SRP), performs and documents regular review of individual subject safety data, and performs review of cumulative safety data with the safety risk lead. As appropriate, the clinical lead may delegate these responsibilities to the study clinician identified in the SRP. The specific components of safety data review are detailed in the Safety Data Review Guide – for Clinicians and in SAF09 SOP. For all studies, clinical safety review should be performed in consultation with a designated medical monitor if neither clinical lead norclinicians are medically qualified.
8. Ensure company’s medical compliance.
  • Act as the sole reviewer to ensure educational grants within medical compliance
  • Review and approve promotional materials and activities to ensure their scientific standard and medical compliance with external and internal requirements
Pfizer is an equal opportunity employer and complies with all applicable equal employment opportunity legislation in each jurisdiction in which it operates. Medical #LI-PFE

工作地點(diǎn)

上海靜安區(qū)中信泰富廣場

職位發(fā)布者

劉一飛/人事經(jīng)理

當(dāng)前在線
立即溝通
公司Logo輝瑞投資有限公司公司標(biāo)簽
輝瑞公司(Pfizer Inc.)創(chuàng)建于1849年,總部位于美國紐約,是一家以科學(xué)為基礎(chǔ)的、創(chuàng)新的、以患者為先的生物制藥公司。輝瑞的使命是“為患者帶來改變其生活的突破創(chuàng)新”。在輝瑞,我們通過科學(xué)和全球資源為人們提供治療方案,以延長其生命,顯著改善其生活。在醫(yī)療衛(wèi)生產(chǎn)品的探索、研發(fā)和生產(chǎn)過程中,輝瑞始終致力于奉行嚴(yán)格的質(zhì)量、安全和價值標(biāo)準(zhǔn)。我們在全球的產(chǎn)品組合包括創(chuàng)新藥品和疫苗。每天,輝瑞在發(fā)達(dá)和新興市場的員工都在推進(jìn)人類健康,推動疾病的預(yù)防、治療和治愈,以應(yīng)對挑戰(zhàn)我們這個時代的頑疾。輝瑞還與醫(yī)療衛(wèi)生服務(wù)方、政府和社區(qū)合作,支持并促進(jìn)世界各地的人們能夠獲得更為可靠和可承付的醫(yī)療衛(wèi)生服務(wù)。這與輝瑞作為一家全球卓越的創(chuàng)新生物制藥公司的責(zé)任是一致的。170余年來,輝瑞一直致力于為所有依賴我們的人帶來改變。輝瑞于1989年進(jìn)入中國市場。扎根中國30余年,輝瑞已成為在華主要的外資制藥公司之一。2021年是輝瑞新征程的開始。迄今已有170余年歷史的輝瑞正在邁入全新時代,成為一家以科學(xué)為基礎(chǔ)的、創(chuàng)新的、以患者為先的生物制藥公司。目前輝瑞在中國業(yè)務(wù)覆蓋全國300余個城市,累計投資超過15億美元,并設(shè)立了1家先進(jìn)的生產(chǎn)設(shè)施,2個研發(fā)中心(分別位于上海張江高科技園區(qū)和武漢光谷),在華有近7,000名員工分布于業(yè)務(wù)、研發(fā)和生產(chǎn)等領(lǐng)域。輝瑞在華上市了五大領(lǐng)域的高品質(zhì)創(chuàng)新產(chǎn)品,包括腫瘤、疫苗、抗感染、炎癥與免疫、罕見病等多個領(lǐng)域的處方藥和疫苗,強(qiáng)大完善的產(chǎn)品線旨在滿足生命各階段的健康需求。
公司主頁